Caxton Associates (UK)’s Charles River Laboratories CRL Stock Holding History

Caxton Associates (UK)’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.31M	Buy	+11,205	New	+$2.95M	0.07%	120

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Ariel Investments Chicago, Illinois $9.6B AUM 22.21% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $25.4B AUM 35.48% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $296B AUM 23.14% 1-Year Est. Return

Caxton Associates (UK)'s CRL Position: Q3 2026 in Review

Caxton Associates (UK) opened a new position in Charles River Laboratories (CRL) in Q3 2026: 11,205 shares worth $3.31M. The stake represents 0.07% of the portfolio and ranks #120 among its holdings.

515 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

Caxton Associates (UK) held 11,205 shares of Charles River Laboratories worth $3.31M as of Q3 2026.
Charles River Laboratories was a new Caxton Associates (UK) position in Q3 2026.
Charles River Laboratories made up 0.07% of Caxton Associates (UK)'s portfolio in Q3 2026, its #120 holding.
515 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Caxton Associates (UK)'s 13F filing for Q3 2026, filed 13 Nov 2026.